FGFR4 and steatosis: The marked net loss in liver fat by FGF19 and NGM282 is likely mediated by the FGFR1c-βKlotho and FGFR4-βKlotho receptor complexes, as an agonistic antibody against FGFR1c-βKlotho reduces steatosis (45) and a compound upregulating CYP7A1 increases steatosis (46).